EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers

Lloyd A Greene, Qing Zhou, Markus D Siegelin, James M Angelastro iD

Cells · 11.02.2023 · 12 (4) · 581

DOI: 10.3390/cells12040581 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.02.2023. Verfasst von Lloyd A Greene und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, The NewYork-Presbyterian Hospital William Rhodes Center for Glioblastoma, Alex’s Lemonade Stand Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing novel therapeutics often follows three steps: target identification, design of strategies to suppress target activity and drug development to implement the strategies. In this review, we recount the evidence identifying the basic leucine zipper transcription factors ATF5, CEBPB, and CEBPD as targets for brain and other malignancies. We describe strategies that exploit the structures of the three factors to create inhibitory dominant-negative (DN) mutant forms that selectively suppress growth and survival of cancer cells. We then discuss and compare four peptides (CP-DN-ATF5, Dpep, Bpep and ST101) in which DN sequences are joined with cell-penetrating domains to create drugs that pass through tissue barriers and into cells. The peptide drugs show both efficacy and safety in suppressing growth and in the survival of brain and other cancers in vivo, and ST101 is currently in clinical trials for solid tumors, including GBM. We further consider known mechanisms by which the peptides act and how these have been exploited in rationally designed combination therapies. We additionally discuss lacunae in our knowledge about the peptides that merit further research. Finally, we suggest both short- and long-term directions for creating new generations of drugs targeting ATF5, CEBPB, CEBPD, and other transcription factors for treating brain and other malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cell-Penetrating PeptidesNeoplasmsHumansBrainDrug DevelopmentCCAAT-Enhancer-Binding Protein-deltaActivating Transcription FactorsCCAAT-Enhancer-Binding Protein-beta

Stichwörter der Autor:innen

ATF5CEBPBCEBPDbrain cancercell-penetratingdecoydominant-negativedrugglioblastomatranscription factor

Substanzen

Cell-Penetrating PeptidesCEBPD protein, humanCCAAT-Enhancer-Binding Protein-deltaATF5 protein, humanActivating Transcription FactorsCEBPB protein, humanCCAAT-Enhancer-Binding Protein-beta

Autor:innen und Institutionen

  • Department of Pathology and Cell Biology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.

ORCID-Profile: James M Angelastro

Förderung

  • NIH HHS
  • The NewYork-Presbyterian Hospital William Rhodes Center for Glioblastoma
  • Alex’s Lemonade Stand Foundation
  • NIH

Zitieren

APA

Greene, L. A., Zhou, Q., Siegelin, M. D., & Angelastro, J. M. (2023). Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells, 12(4), 581. https://doi.org/10.3390/cells12040581

Vancouver

Greene LA, Zhou Q, Siegelin MD, Angelastro JM. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells. 2023;12(4):581. doi:10.3390/cells12040581

BibTeX
@article{Greene2023,
  author = {Greene, Lloyd A and Zhou, Qing and Siegelin, Markus D and Angelastro, James M},
  title = {Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {581},
  doi = {10.3390/cells12040581}
}
Kostenlos starten →